U.S. Markets closed
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • Dow 30

    34,200.67
    +164.68 (+0.48%)
     
  • Nasdaq

    14,052.34
    +13.58 (+0.10%)
     
  • Russell 2000

    2,262.67
    +5.60 (+0.25%)
     
  • Crude Oil

    63.07
    -0.39 (-0.61%)
     
  • Gold

    1,777.30
    +10.50 (+0.59%)
     
  • Silver

    26.04
    +0.08 (+0.29%)
     
  • EUR/USD

    1.1980
    +0.0004 (+0.0359%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3840
    +0.0056 (+0.4069%)
     
  • USD/JPY

    108.7830
    +0.0670 (+0.0616%)
     
  • BTC-USD

    54,801.70
    -6,479.95 (-10.57%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.68 (+0.14%)
     

AstraZeneca/Merck's PARP Inhibitor In Late-Stage Breast Cancer Study To Enter Early Analysis

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Based on the planned interim analysis, the Independent Data Monitoring Committee (IDMC) has recommended that OlympiA Phase 3 trial evaluating AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) Lynparza (olaparib) will move to early primary analysis and reporting.

  • According to IDMC, the trial crossed the superiority boundary for its primary endpoint of invasive disease-free survival (iDFS). It demonstrated a sustainable, clinically relevant treatment effect for Lynparza versus placebo for patients with germline BRCA-mutated high-risk human epidermal growth factor receptor 2-negative early breast cancer.

  • Lynparza (olaparib) is a PARP inhibitor and targets to block DNA damage response (DDR) in cells/tumors harboring a deficiency in homologous recombination repair (HRR), such as mutations in BRCA1 and/or BRCA2.

  • Lynparza is currently approved in the U.S., the EU, Japan, China, and several other countries for ovarian cancer, breast cancer, and prostate cancer subsets.

  • Price Action: AZN and MRK stock moved 0.06% and 0.40% at $50.92 $74.55, respectively, in the premarket trading on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.